Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory condi…
An institutional-grade, numbers-driven thesis on AMGN — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Amgen Inc. (AMGN) 67/100 with a 12-month base-case forecast of $371.61 — -8.2% versus the current price of $404.85. Amgen Inc. trades at $404.85 in the Healthcare sector, with a market capitalisation of $218.50B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for AMGN is $371.61, implying -8.2% versus the current price. The model's 12-month scenario range runs from $509.70 (bear) to $587.52 (bull), with a base case of $529.62.
On the fundamentals, Amgen shows a P/E of 25.0, trailing revenue of $36.74B, revenue growth of +9.9% YoY, a dividend yield of 2.42%. This page also tracks AMGN's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
AMGN currently carries a TradersQuant composite score of 67/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $371.61 implies -8.2% from $404.85. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for AMGN is $371.61, about -8.2% versus the latest price of $404.85. Consensus is based on 39 analysts.
TradersQuant's 12-month model forecast for AMGN is a base case of $529.62, ranging from $509.70 (bear) to $587.52 (bull), an expected return of +30.8%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for AMGN over the next 12 months is $529.62 in the base case (bear $509.70, bull $587.52), versus today's price of $404.85. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for AMGN — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates AMGN's fair value at $371.61, implying -8.2% of expected upside versus the current price.
Yes — Amgen pays a dividend yielding 2.42% (about $9.80 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
